iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
The next generation of weight-loss medicines is partly here: the U.S. FDA approved the once-daily pill Foundayo (orforglipron) on April 1, 2026, for certain adults with obesity or overweight. Other closely watched drugs—including retatrutide, survodutide and the cagrilintide–semaglutide combination CagriSema—have late-stage trial results, but those findings do not make them approved treatments. The distinction matters: a strong trial result, a company’s plan to seek approval and an FDA authorization are different things.
Which new weight-loss drugs are approved?
Foundayo (orforglipron): FDA-approved in the United States
On April 1, 2026, the FDA approved Foundayo, an oral GLP-1 receptor partial agonist, for use with a reduced-calorie diet and increased physical activity. The indicated population is adults with obesity, or adults with overweight and at least one weight-related comorbid condition. The FDA says it is intended to reduce excess body weight and maintain weight reduction long term. Its announcement noted that the pill does not need to be taken on an empty stomach.
FDA approval applies to this medicine and its approved use; it does not mean that every GLP-1 product, compounded formulation or drug candidate is approved. The agency’s April 1 announcement quoted Acting Center for Drug Evaluation and Research Director Tracy Beth Høeg, M.D., Ph.D.: “Individuals who are overweight or obese now have an additional option for weight loss — a GLP-1 receptor partial agonist pill which does not need to be taken on an empty stomach.”
Free tools Windows power users keep installed
One-click scans. No signup required.
Which other promising drugs are still investigational?
Retatrutide
Retatrutide remains investigational and is not FDA-approved, according to Eli Lilly’s information available in July 2026. On July 23, the company said it planned to submit a biologics license application to the FDA in the first quarter of 2027, following additional positive phase 3 results. That is a company plan, not an FDA decision or a guaranteed approval date.
#1 Best Overall
Survodutide
Survodutide is described as an investigational glucagon receptor–GLP-1 receptor dual agonist in its phase 3 publication. The published results establish trial findings; they do not establish that the FDA has approved it or that a filing has occurred.
CagriSema
CagriSema is the cagrilintide–semaglutide combination. Phase 3a trial findings have been published, but those publications do not establish its current approval or filing status. A trial result should not be read as a prescription option.
What have the late-stage trials found?
The following figures come from separate placebo-controlled studies. They are estimated group averages under each trial’s design—not predictions of what an individual will lose—and should not be treated as a head-to-head ranking.
| Medicine and trial | Participants and duration | Reported mean weight change |
|---|---|---|
| Retatrutide, TRIUMPH-1; Eli Lilly-funded investigators, 2026 | 2,339 adults with obesity without diabetes; weekly injections for 80 weeks | −17.6% at 4 mg, −23.7% at 9 mg and −25.0% at 12 mg, versus −3.9% with placebo |
| Survodutide, SYNCHRONIZE-1; Boehringer Ingelheim-funded investigators, 2026 | 725 adults with obesity without diabetes; weekly injections adjusted up to 3.6 or 6.0 mg; week 76 results under the treatment-regimen estimand | −12.2% at 3.6 mg and −13.0% at 6.0 mg, versus −5.4% with placebo |
| CagriSema, REDEFINE 1 investigators, 2025 | Adults without diabetes; phase 3a study, 68 weeks | Estimated mean −20.4% with the combination, versus −3.0% with placebo |
How to interpret the percentages
The trials differed in who enrolled, treatment duration, dose, analysis method and placebo response. For example, the survodutide figures above use a treatment-regimen estimand, while the CagriSema figure is an estimated mean. Those differences, along with each study’s discontinuations and adverse-event profile, prevent a fair conclusion that one medicine is more effective based on these percentages alone.
The cited CagriSema phase 3a study in adults with overweight or obesity and type 2 diabetes also ran for 68 weeks and found significantly lower body weight with the combination than with placebo. The specific effect estimate is not included here, so it should not be inferred from the separate study in adults without diabetes.
Side effects reported in the cited trials
Gastrointestinal events were the most common adverse events in the reported retatrutide trial. In SYNCHRONIZE-1, gastrointestinal symptoms—typically mild to moderate—were the most common adverse events with survodutide. These trial reports do not establish how any particular patient will respond.
Rank #4
Why can’t you pick a winner from these studies?
Each percentage answers a question about one medicine in one trial, under a particular protocol. A valid comparison would need to account for the enrolled population and starting characteristics, treatment duration and dose, analysis method, placebo response, discontinuations and adverse events. The cited studies are not direct comparisons of the drugs against one another, so comparing their headline percentages as if they were tested in the same people would be misleading.
PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchWhat is changing in the next wave of obesity treatment?
The developments point in several directions at once: an oral option that is already approved, investigational medicines with published phase 3 results, and a combination approach studied in phase 3a. That creates more potential choices to evaluate, but it does not identify one universally best medicine. The evidence summarized here is not a complete catalog of every obesity-drug candidate, and study results alone do not establish which treatment is appropriate for an individual.
Are unapproved weight-loss drugs or online peptides safe alternatives?
No. The FDA has warned about unapproved GLP-1 products marketed for weight loss, including complaints that compounded products were shipped without adequate cooling. An investigational medicine is not an approved treatment, and an online product labeled “research use only” should not be treated as equivalent to medicine used in a clinical trial. Regulatory status and product quality are separate from a compound’s reported trial results.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
